Zetpil™ Seratone Cream


  • Strong clinical evidence for the use of 5-HTP for depression, anxiety and panic attacks, insomnia, migraine headaches, obesity, and obsessive compulsive disorders (OCD).*
  • May help alleviate stress levels and pain associated with Fibromyalgia*
  • Unlike other 5-HTP-based products, Zetpil™ Seratone can deliver a therapeutic dosage of this important serotonin precursor directly into the bloodstream, bypassing oral absorption issues and the unwanted side effects (nausea, diarrhea or vomiting) often associated with oral ingestion of 5-HTP (5-Hydroxytryptophan).*
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


Zetpil™ Cream Advantage

Zetpil™ delivers nutrition through the skin with the use of deep-penetrating, ultra-absorbable creams that have a unique, proprietary formulated base that has revolutionized not only this mode of delivery, but also the ability to obtain nutrients in a far more efficacious method.  These creams are a result of combining natural ingredients with a non-irritating, rapidly absorbable, antioxidant base and delivering the nutrients directly into the bloodstream in less than 10 minutes in a highly effective manner. Oral supplements are exposed to the hazards of stomach acid, digestive enzymes, food-related breakdown, first pass metabolism, and other bioavailability issues in the gastro-intestinal system.

Additionally, many raw materials simply have a very low bioavailability , and only achieve around 10% or less absorption rates, even if the patient is in optimal health condition. Compromised health, age, or certain conditions that result in inability to take oral nutrients often preclude these patient populations from obtaining the necessary nutrition to stay healthy which often exacerbates chronic health issues.

Zetpil™ deep penetrating creams, are a NOW solution to delivering the necessary nutrients to patients, on a daily basis, that is both easy and cost effective.

Current Treatments for Depression

Depression, insomnia, addiction, obsessive or compulsive behavior, PMS, obesity and anxiety have become amongst the most prevalent and frequently recurring disorders in the modern world. These conditions often lead to long-term use of prescription drugs and for most, these battles last a lifetime.

Selective Serotonin Reuptake Inhibitors (SSRIs hereafter) are approved by the Food and Drug Administration (FDA) to treat depression and are the most commonly prescribed antidepressants. Common examples of SSRIs are citalopram, fluoxetine, paroxetine and sertraline.

“SSRIs ease depression by affecting naturally occurring chemical messengers (neurotransmitters), which are used to communicate between brain cells. SSRIs block the reabsorption (re-uptake) of the neurotransmitter serotonin in the brain. Changing the balance of serotonin seems to help brain cells send and receive chemical messages, which in turn boosts mood. “

“Most antidepressants work by changing the levels of one or more neurotransmitters. SSRIs are called selective because they seem to primarily affect serotonin, not other neurotransmitters.”http://www.mayoclinic.org/diseases-conditions/depression/in-depth/ssris/art-20044825

The serotoninergic system is known to modulate mood, emotion, sleep and appetite and thus is implicated in the control of numerous behavioral and physiological functions. Decreased serotoninergic neurotransmission has been proposed to play a key role in the etiology (cause) of depression and associated conditions.

However, despite the widespread use of anti-depressant medications to influence the serotoninergic system, two-thirds (2/3) of patients do not achieve remission or even regain normal quality of life.

Even more discouraging are the new discussions from the pharmaceutical industry admitting that anti-depressants alone do not achieve acceptable success rates, and for those a second pharmaceutical intervention is recommended.  Physicians are now prescribing anti-psychotic medicines, in addition to SSRIs, such as aripiprazole (aka: Abilify).  Unfortunately adding more drugs only compounds the side effects.

Is there a Safe, Effective, and Natural Alternative?

SSRI’s can often have unpleasant side effects especially in prolonged use. A natural alternative is supplementation with L-5-Hydroxytryptophan (5-HTP), the direct serotonin precursor in the brain, which works by providing more of the base raw material the body needs to metabolize serotonin and therefore naturally raise serotonin levels. Unlike SSRI’s, 5-HTP has few known side effects.

Recent research suggests that Griffonia Seeds P.E., derived from the herb Griffonia Simplicifolia, contain a high concentration of L-5-HTP (5-Hydroxytryptophan), and offers a natural alternative to help manage depressive or compulsive conditions which are often characterized by a common biochemical origin, serotonin deficiency.

5-HTP has been clinically shown to safely and effectively raise serotonin levels in the brain.  Serotonin helps support the regulation of endocrine and brain activity responsible for emotion, appetite and sleep/wake cycles and has been proven effective in treating problems such as depression, insomnia, eating disorders, fibromyalgia and migraine headaches.

5-HTP does not interfere with the normal process of serotonin release or re-absorption.  It is not a drug but an amino acid produced naturally by your body from tryptophan.  5-HTP offers an “individualized” approach because the brain inherently self-regulates 5-HTP uptake depending on saturation.


Neurochemical, behavioral and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice

Psychopharmacology (Berl) Dec 2008; 201(2): 203–218

Meredith A. Fox, et al



Serotonin and central nervous system fatigue: nutritional considerations

Am J Clin Nutr 2000 Aug; 72(2 Suppl):573S-8S

Davis JM, et al



Serotonin and hypothalamic control of hunger: a review

Rev. Assoc. Med. Bras. vol.57 no.1 São Paulo Jan/Feb. 2011

Fernanda de Matos Feijó, et al



Serotonin synthesis, release and reuptake in terminals: a mathematical model

Theor Biol Med Model 2010; 7: 34.

Janet Best, et al



The role of serotonin receptor subtypes in treating depression: a review of animal studies

Psychopharmacology (Berl)  2011 Feb; 213(2-3):265-87

Carr GV, et al



The use of serotonergic drugs to treat obesity – is there any hope?

Drug Des Devel Ther 2011; 5: 95–109

Nicholas T Bello, et al



Chronic SSRI Treatment Exacerbates Serotonin Deficiency in Humanized Tph2 Mutant Mice

William B. Siesser, et al

ACS Chem Neurosci 2013 Jan 16; 4(1): 84–88


Additional information

Weight 5.5 oz
Dimensions 2 × 2 × 5 in